"Ex vivo" surgery works for abdominal tumors

Share this article:

A novel surgical technique that involves the temporary removal of entire abdominal organs enables surgeons to take out tumors that are unresectable by the usual surgical methods.

In their case report, published in American Journal of Transplantation (2012;12[5]:1323-1328), a team of surgeons led by Tomoaki Kato, MD, of Columbia University, New York, New York, described their removal of tumors in three patients. The tumors involved both the celiac artery and the superior mesenteric artery.

In this new approach, known as multivisceral ex vivo surgery, the entire abdominal viscera were removed, the tumor was cut out, and the blood vessels were reconstructed using synthetic vascular grafts. The organs were then reimplanted into the abdomen, with surgeons reconnecting blood vessels and GI tracts.

All three patients remain alive with no tumor recurrence at 17, 27, and 38 months after surgery. Postoperative complications included diarrhea, sphincter of Oddi dysfunction, and arterial stenosis, all of which responded to directed treatments.

The authors conclude that multivisceral ex vivo surgery may prove to be a useful treatment for tumors thought of as inoperable. They contend that the surgery is most suitable for locally invasive tumors that are unresectable due to location and vascular involvement.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.